Related Experiment Video

Updated: May 22, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer

Arne R M van der Bilt1, Elisabeth G E de Vries, Steven de Jong

  • 1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands.

Critical Reviews in Oncology/Hematology
|April 25, 2012
PubMed

Insights

Angiogenesis inhibitors show modest effects in advanced ovarian cancer, necessitating further research. Biomarkers are crucial for predicting patient response to these targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epithelial ovarian cancer outcomes remain poor with standard chemotherapy.
  • Targeted therapies, particularly anti-angiogenesis agents, are being explored.
  • Vascular Endothelial Growth Factor (VEGF) pathway is a key target in ovarian carcinogenesis.

Purpose of the Study:

  • To review current and ongoing studies of angiogenesis inhibitors in ovarian cancer.
  • To discuss biomarkers for predicting response to anti-angiogenesis therapies.
  • To explore preclinical data on novel angiogenesis inhibitors.

Main Methods:

  • Review of clinical trials (Phase II and III) involving angiogenesis inhibitors.
  • Analysis of data on bevacizumab and VEGFR-targeted tyrosine kinase inhibitors.
  • Inclusion of preclinical studies and biomarker research.

Main Results:

  • Angiogenesis inhibitors demonstrated efficacy in Phase II trials.
  • Bevacizumab added to chemotherapy showed a modest effect in Phase III trials.
  • Initial expectations for these agents have been moderated.

Conclusions:

  • Further research is essential to establish the role of angiogenesis inhibitors in ovarian cancer treatment.
  • Biomarker identification is critical for personalized treatment strategies.
  • Ongoing and preclinical studies may offer new therapeutic avenues.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...